Patrícia Silva, PhD,  director of science content—

Researchers at The University of British Columbia (UBC) recently opened a clinical trial designed to assess the sensation of shortness of breath or dyspnea in patients with cystic fibrosis (CF) during exercise. The study, titled “Qualitative Descriptors of Dyspnea During Exercise in Cystic Fibrosis”…

A study published in the journal Alcoholism: Clinical and Experimental Research revealed that the heavy drinking habits of lung donors can influence the outcome of lung transplantation in recipient patients. The study is entitled “Heavy Alcohol Use in Lung Donors…

Proteostasis Therapeutics, Inc. (PTI), a biotechnology company focused on discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis, has just revealed a novel class of therapeutics called, CFTR Amplifiers, indicated for cystic fibrosis (CF). These agents work to enhance…

Celtaxsys, Inc., a privately-owned, clinical stage drug discovery and development company focused on addressing serious inflammatory diseases, has just announced the U.S. Food and Drug Administration has granted the company’s experimental therapy CTX-4430 (oral leukotriene A4 hydrolase inhibitor) Orphan Drug Designation as a potential treatment…

Norwood, Massachusetts-based Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company specializing in the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory-fibrotic diseases, has just announced it has been invited to present at this week’s 17th Annual BIO CEO & Investor Conference. The conference, which will take place from February 9 to…

UK-based non-profit organization, Cystic Fibrosis Trust, recently launched a new awareness campaign that seeks to empower individuals living with cystic fibrosis (CF) to find out which specific CFTR gene mutation they are carrying. When patients know their specific mutation, physicians can prescribe more targeted, effective treatments, and even help patients participate in appropriate clinical…

A new report on cystic fibrosis (CF) in England and Wales further supports evidence of the groundbreaking impact that Kalydeco (ivacaftor) has had on treating CF, and reinforces the Cystic Fibrosis Trust‘s urgency for the drug to be made available to the 44 patients with rare CF gene mutations in…

The Cystic Fibrosis Foundation, a nonprofit donor-supported organization and world leader in the search for a cystic fibrosis cure, recently issued guidelines on the diagnosis and treatment of the disease. These guidelines were conceived by a committee of experts based on the available literature and clinical evidence reported.

President Barack Obama, during his recent State of the Union Address, highlighted cystic fibrosis (CF) as the nation’s model for the White House’s upcoming strengthened strategy for “precision medicine,” or groundbreaking treatments that specifically target “chinks” in a disease’s “armor” — commonly found all the way down to a…

Galapagos NV, a Belgium-based, clinical stage biotech company focused on developing novel mode of action medicines, recently announced it has received a €2.5 million grant from the Flemish Agency for Innovation through Science and Technology (IWT), which is meant to fund the company’s further research and development of new antibiotics. Working…